BackgroundKininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e. g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
DescriptionKNG1 Polyclonal Antibody. Unconjugated. Raised in: Rabbit.
Formulation0.03% Proclin 300, 50% Glycerol, 0.01M PBS, PH 7.4.
SpecificityHuman
IsotypeIgG
Uniprot IDP01042
PurificationProtein G purified
ImmunogenRecombinant Human Kininogen-1 protein (390-644AA)
StorageShipped at 4°C. Upon delivery aliquot and store at -20°C (short-term) or -80°C (long-term). Avoid repeated freeze.
Alternative NamesAlpha-2-thiol proteinase inhibitor, Fitzgerald factor, High molecular weight kininogen, Williams-Fitzgerald-Flaujeac factor, KNG1, BDK, KNG
ApplicationELISA, WB, IHC, IF; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200, IF:1:50-1:200